Featured Research

from universities, journals, and other organizations

Skin Cancer Breakthrough? New Molecule Shows Promise In Patients With Advanced Basal Cell Carcinoma

Date:
April 15, 2008
Source:
American Association for Cancer Research
Summary:
A novel molecule, GDC-0449, shrinks tumors for patients with advanced basal cell carcinoma with limited side effects, suggesting a viable new treatment option for patients with the advanced form of this cancer. "Basal cell carcinoma affects about one million people a year, and a very small fraction of these patients have disease that is not curable with surgery. We currently do not have any treatments that can effectively slow tumor growth in these advanced patients. This finding has enormous implications in this population," said one of the physicians involved with the research.

A novel molecule, GDC-0449, shrinks tumors for patients with advanced basal cell carcinoma with limited side effects, suggesting a viable new treatment option for patients with the advanced form of this cancer, according to research presented at the 2008 Annual Meeting of the American Association for Cancer Research.

"Basal cell carcinoma affects about one million people a year, and a very small fraction of these patients have disease that is not curable with surgery. We currently do not have any treatments that can effectively slow tumor growth in these advanced patients. This finding has enormous implications in this population," said Daniel D. Von Hoff, M.D., physician in chief at the Translational Genomics Research Institute (TGen) and chief medical officer for the Scottsdale Clinical Research Institute at Scottsdale Healthcare in Arizona.

GDC-0449 works by inhibiting the Hedgehog pathway. The Hedgehog ligands are a family of proteins that are important in tissue growth and repair. The ligands signal via two cell surface receptors called PTCH and SMO. Abnormal activation of Hedgehog signaling pathway because of mutations in PTCH and SMO is the cause of most basal cell carcinomas.

Von Hoff presented data from a phase I trial conducted at Scottsdale Healthcare, Karmanos Cancer Institute at Wayne State University, and the Sidney Kimmel Cancer Center at Johns Hopkins. This trial tested GDC-0449 in humans for the first time. Researchers enrolled nine patients with advanced basal cell carcinoma. Patients received oral doses of GDC-0449 once a day continuously.

Durable clinical benefit, defined as tumor stabilization or shrinkage visible on X-ray or other physical exam, was observed in eight of patients evaluated, and lasted a median of over 176 days. The first patient treated in the trial has shown clinical improvement for over 438 days, Von Hoff says, with mild side effects. "He came to us short of breath and in pain, but he has had a very dramatic response with this drug," Von Hoff said.

Of the original nine patients, two have had shrinkage of their tumors as measured by computerized tomography (CT) scans, four have had shrinkage or improvement of their tumors by clinical exam, two have had prolonged periods without tumor growth, and one has had significant tumor growth.

Further evaluations of the study participants measured the presence of GLI1, a genetic marker of Hedgehog pathway activity, in skin cells sampled from the participants. Among all patients tested to date, there was a reduction in this marker, indicating that the drug was affecting the Hedgehog pathway.

"The drug has been extremely well tolerated. Some patients lose a sense of taste, and there has been a small amount of hair loss and weight loss, but the toxicity has been mild," Von Hoff said.

Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients: Abstract LB-138


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Skin Cancer Breakthrough? New Molecule Shows Promise In Patients With Advanced Basal Cell Carcinoma." ScienceDaily. ScienceDaily, 15 April 2008. <www.sciencedaily.com/releases/2008/04/080414161050.htm>.
American Association for Cancer Research. (2008, April 15). Skin Cancer Breakthrough? New Molecule Shows Promise In Patients With Advanced Basal Cell Carcinoma. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2008/04/080414161050.htm
American Association for Cancer Research. "Skin Cancer Breakthrough? New Molecule Shows Promise In Patients With Advanced Basal Cell Carcinoma." ScienceDaily. www.sciencedaily.com/releases/2008/04/080414161050.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
CDC Calls for New Ebola Safety Guidelines

CDC Calls for New Ebola Safety Guidelines

AP (Oct. 20, 2014) Centers for Disease Control and Prevention Director Dr. Tom Frieden laid out new guidelines for health care workers when dealing with the deadly Ebola virus including new precautions when taking off personal protective equipment. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins